WO2002055692A3 - Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung - Google Patents

Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung Download PDF

Info

Publication number
WO2002055692A3
WO2002055692A3 PCT/EP2002/000151 EP0200151W WO02055692A3 WO 2002055692 A3 WO2002055692 A3 WO 2002055692A3 EP 0200151 W EP0200151 W EP 0200151W WO 02055692 A3 WO02055692 A3 WO 02055692A3
Authority
WO
WIPO (PCT)
Prior art keywords
target gene
inhibiting
expression
medicament
treating
Prior art date
Application number
PCT/EP2002/000151
Other languages
English (en)
French (fr)
Other versions
WO2002055692A2 (de
Inventor
Roland Kreutzer
Stefan Limmer
Hans-Peter Vornlocher
Philipp Hadwiger
Anke Geick
Matthias Ocker
Christoph Herold
Detlef Schuppan
Original Assignee
Ribopharma Ag
Roland Kreutzer
Stefan Limmer
Hans-Peter Vornlocher
Philipp Hadwiger
Anke Geick
Matthias Ocker
Christoph Herold
Detlef Schuppan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7669989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002055692(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE10163098A priority Critical patent/DE10163098B4/de
Application filed by Ribopharma Ag, Roland Kreutzer, Stefan Limmer, Hans-Peter Vornlocher, Philipp Hadwiger, Anke Geick, Matthias Ocker, Christoph Herold, Detlef Schuppan filed Critical Ribopharma Ag
Priority to DE50214266T priority patent/DE50214266D1/de
Priority to AT02702247T priority patent/ATE460481T1/de
Priority to CA002432341A priority patent/CA2432341A1/en
Priority to JP2002556739A priority patent/JP4209678B2/ja
Priority to EP02702247A priority patent/EP1349927B1/de
Priority to DE10230996A priority patent/DE10230996A1/de
Priority to DE10230997A priority patent/DE10230997A1/de
Publication of WO2002055692A2 publication Critical patent/WO2002055692A2/de
Priority to PCT/EP2002/011432 priority patent/WO2003033700A1/de
Priority to US10/493,768 priority patent/US20040248835A1/en
Priority to PCT/EP2002/011970 priority patent/WO2003035870A1/de
Priority to PCT/EP2002/011968 priority patent/WO2003035868A1/de
Priority to EP10011813.2A priority patent/EP2264173A3/de
Priority to JP2003538376A priority patent/JP2005506087A/ja
Priority to PCT/EP2002/011971 priority patent/WO2003035082A1/de
Priority to PCT/EP2002/011973 priority patent/WO2003035876A1/de
Priority to PCT/EP2002/011969 priority patent/WO2003035869A1/de
Priority to CNA02826181XA priority patent/CN1608133A/zh
Priority to EP02801917A priority patent/EP1438056A1/de
Priority to PCT/EP2002/011972 priority patent/WO2003035083A1/de
Priority to CNA028261798A priority patent/CN1608131A/zh
Priority to EP02779511A priority patent/EP1438405A1/de
Priority to CNA028251636A priority patent/CN1604783A/zh
Priority to EP02785313A priority patent/EP1438409A1/de
Priority to US10/493,686 priority patent/US20050119202A1/en
Priority to JP2003537650A priority patent/JP2005512976A/ja
Priority to JP2003538370A priority patent/JP2005506385A/ja
Priority to EP02785312A priority patent/EP1438406A1/de
Priority to US10/384,434 priority patent/US20040121348A1/en
Priority to US10/384,512 priority patent/US7348314B2/en
Priority to US10/384,260 priority patent/US7473525B2/en
Priority to US10/384,463 priority patent/US7763590B2/en
Publication of WO2002055692A3 publication Critical patent/WO2002055692A3/de
Priority to US10/382,634 priority patent/US20040038921A1/en
Priority to US10/666,458 priority patent/US20040126791A1/en
Priority to US10/941,663 priority patent/US7767802B2/en
Priority to US11/229,183 priority patent/US7423142B2/en
Priority to US11/747,549 priority patent/US20080070856A1/en
Priority to US11/959,936 priority patent/US7745418B2/en
Priority to US12/175,938 priority patent/US7868160B2/en
Priority to US12/631,689 priority patent/US8273868B2/en
Priority to US12/817,009 priority patent/US7994309B2/en
Priority to US12/961,337 priority patent/US8143390B2/en
Priority to US13/177,316 priority patent/US8273870B2/en
Priority to US13/594,150 priority patent/US20130064879A1/en
Priority to US13/594,140 priority patent/US20120322858A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

Die Erfindung betrifft ein Verfahren zur Hemmung einer die Apoptose einer Tumorzelle hemmenden oder verhindernden Expression mindestens eines Zielgens, wobei mindestens eine doppelsträngige Ribonukleinsäure (dsRNA) in die Tumorzelle eingeführt wird, deren einer Strang S1 einen zum Zielgen zumindest abschnittsweise komplementären aus weniger als 25 aufeinanderfolgenden Nukleotiden bestehenden Bereich aufweist.
PCT/EP2002/000151 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung WO2002055692A2 (de)

Priority Applications (45)

Application Number Priority Date Filing Date Title
DE10163098A DE10163098B4 (de) 2001-10-12 2001-12-20 Verfahren zur Hemmung der Replikation von Viren
DE50214266T DE50214266D1 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
AT02702247T ATE460481T1 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
CA002432341A CA2432341A1 (en) 2001-01-09 2002-01-09 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
JP2002556739A JP4209678B2 (ja) 2001-01-09 2002-01-09 標的遺伝子の発現を阻害する方法および腫瘍を治療するための医薬
EP02702247A EP1349927B1 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
DE10230996A DE10230996A1 (de) 2001-10-26 2002-07-09 Medikament zur Behandlung eines Pankreaskarzinoms
DE10230997A DE10230997A1 (de) 2001-10-26 2002-07-09 Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
PCT/EP2002/011432 WO2003033700A1 (de) 2001-10-12 2002-10-11 Verfahren zur hemmung der replikation von viren
JP2003538370A JP2005506385A (ja) 2001-10-26 2002-10-25 膵臓癌を処置するための医薬
EP02785312A EP1438406A1 (de) 2001-10-26 2002-10-25 Medikament zur behandlung eines pankreaskarzinoms
EP02779511A EP1438405A1 (de) 2001-01-09 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
EP02801917A EP1438056A1 (de) 2001-10-26 2002-10-25 Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
PCT/EP2002/011968 WO2003035868A1 (de) 2001-10-26 2002-10-25 Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
EP10011813.2A EP2264173A3 (de) 2001-01-09 2002-10-25 Verwendung einer doppelsträngigen Ribonukleinsäure zur gezielten Hemmung der Expression eines vorgegebenen Zielgens
JP2003538376A JP2005506087A (ja) 2001-10-26 2002-10-25 プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用
PCT/EP2002/011971 WO2003035082A1 (de) 2001-10-26 2002-10-25 Medikament zur hemmung der expression eines zielgens
PCT/EP2002/011973 WO2003035876A1 (de) 2001-10-26 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
PCT/EP2002/011969 WO2003035869A1 (de) 2001-10-26 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
CNA02826181XA CN1608133A (zh) 2001-10-26 2002-10-25 双链核糖核酸用于治疗正(+)链rna病毒感染的用途
PCT/EP2002/011970 WO2003035870A1 (de) 2001-10-26 2002-10-25 Medikament zur behandlung eines pankreaskarzinoms
PCT/EP2002/011972 WO2003035083A1 (de) 2001-10-26 2002-10-25 Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
CNA028261798A CN1608131A (zh) 2001-10-26 2002-10-25 治疗胰腺癌的药物
US10/493,768 US20040248835A1 (en) 2001-10-26 2002-10-25 Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
CNA028251636A CN1604783A (zh) 2001-10-26 2002-10-25 通过rna干扰治疗纤维化疾病的药物
EP02785313A EP1438409A1 (de) 2001-10-26 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
US10/493,686 US20050119202A1 (en) 2001-10-26 2002-10-25 Medicament to treat a fibrotic disease
JP2003537650A JP2005512976A (ja) 2001-10-26 2002-10-25 Ｒｎａ干渉により線維化疾患を処置するための医薬
US10/384,463 US7763590B2 (en) 2001-10-12 2003-03-07 Compositions and methods for inhibiting expression of a mutant gene
US10/384,512 US7348314B2 (en) 2001-10-12 2003-03-07 Compositions and methods for inhibiting viral replication
US10/384,434 US20040121348A1 (en) 2001-10-26 2003-03-07 Compositions and methods for treating pancreatic cancer
US10/384,260 US7473525B2 (en) 2001-01-09 2003-03-07 Compositions and methods for inhibiting expression of anti-apoptotic genes
US10/382,634 US20040038921A1 (en) 2001-10-26 2003-08-11 Composition and method for inhibiting expression of a target gene
US10/666,458 US20040126791A1 (en) 2001-10-26 2003-09-19 Compositions and methods for treating trail-resistant cancer cells
US10/941,663 US7767802B2 (en) 2001-01-09 2004-09-15 Compositions and methods for inhibiting expression of anti-apoptotic genes
US11/229,183 US7423142B2 (en) 2001-01-09 2005-09-15 Compositions and methods for inhibiting expression of anti-apoptotic genes
US11/747,549 US20080070856A1 (en) 2001-10-26 2007-05-11 Medicament to treat a fibrotic disease
US11/959,936 US7745418B2 (en) 2001-10-12 2007-12-19 Compositions and methods for inhibiting viral replication
US12/175,938 US7868160B2 (en) 2001-01-09 2008-07-18 Compositions and methods for inhibiting expression of anti-apoptotic genes
US12/631,689 US8273868B2 (en) 2001-10-12 2009-12-04 Compositions and methods for inhibiting viral replication
US12/817,009 US7994309B2 (en) 2001-10-26 2010-06-16 Compositions and methods for inhibiting expression of a mutant gene
US12/961,337 US8143390B2 (en) 2001-01-09 2010-12-06 Compositions and methods for inhibiting expression of anti-apoptotic genes
US13/177,316 US8273870B2 (en) 2001-10-26 2011-07-06 Compositions and methods for inhibiting expression of a mutant gene
US13/594,150 US20130064879A1 (en) 2001-10-12 2012-08-24 Compositions and Methods for Inhibiting Viral Replication
US13/594,140 US20120322858A1 (en) 2001-10-26 2012-08-24 Compositions and Methods for Inhibiting Expression of a Mutant Gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10100586.5 2001-01-09
DE10100586A DE10100586C1 (de) 2001-01-09 2001-01-09 Verfahren zur Hemmung der Expression eines Ziegens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000012 Continuation WO2002053672A1 (de) 2001-01-04 2002-01-03 Holzwerkstoffe aus mit polyisocyanaten verleimten holzteilen

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/EP2002/000152 Continuation WO2002055693A2 (de) 1999-11-24 2002-01-09 Verfahren zur hemmung der expression eines zielgens
PCT/EP2002/011969 Continuation WO2003035869A1 (de) 2001-01-09 2002-10-25 Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US10/384,260 Continuation-In-Part US7473525B2 (en) 2001-01-09 2003-03-07 Compositions and methods for inhibiting expression of anti-apoptotic genes
US10/384,260 Continuation US7473525B2 (en) 2001-01-09 2003-03-07 Compositions and methods for inhibiting expression of anti-apoptotic genes

Publications (2)

Publication Number Publication Date
WO2002055692A2 WO2002055692A2 (de) 2002-07-18
WO2002055692A3 true WO2002055692A3 (de) 2003-06-12

Family

ID=7669989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000151 WO2002055692A2 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung

Country Status (10)

Country Link
US (1) US7473525B2 (de)
EP (3) EP2365075A1 (de)
JP (1) JP4209678B2 (de)
CN (1) CN1650010A (de)
AT (1) ATE460481T1 (de)
CA (1) CA2432341A1 (de)
DE (2) DE10100586C1 (de)
ES (1) ES2204360T3 (de)
WO (1) WO2002055692A2 (de)
ZA (2) ZA200304127B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8394628B2 (en) 2000-03-30 2013-03-12 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202846B2 (en) * 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP2264173A3 (de) 2001-01-09 2015-01-14 Alnylam Europe AG Verwendung einer doppelsträngigen Ribonukleinsäure zur gezielten Hemmung der Expression eines vorgegebenen Zielgens
WO2003035869A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
WO2003010180A1 (en) 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
JP4242590B2 (ja) 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1442143A4 (de) * 2002-02-20 2005-02-16 Sirna Therapeutics Inc DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)
US20040009946A1 (en) 2002-05-23 2004-01-15 Ceptyr, Inc. Modulation of PTP1B expression and signal transduction by RNA interference
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20050245492A1 (en) 2004-04-28 2005-11-03 Lephart Edwin D Use of equol for treating skin diseases
JP2006515158A (ja) 2002-08-01 2006-05-25 シティ・オブ・ホープ ｓｉＲＮＡ発現カセットを合成するための方法およびキット
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
CA2504929C (en) * 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
JP4526228B2 (ja) * 2002-11-22 2010-08-18 隆 森田 ＲＮＡｉによる新規治療法および治療剤
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
GB0306148D0 (en) * 2003-03-18 2003-04-23 Milner Jo Regulation of gene expression
CN1795274A (zh) * 2003-03-26 2006-06-28 多单元免疫治疗公司 诱导细胞死亡和/或凋亡的选定的rna基序
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
JP4505749B2 (ja) 2003-05-30 2010-07-21 日本新薬株式会社 Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
CA2527301A1 (en) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
EP2314692B1 (de) 2003-06-02 2021-02-24 University of Massachusetts Verfahren und Zusammensetzungen zur Verbesserung der RNAi-Wirksamkeit und -Spezifizität
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
CA2528012C (en) 2003-06-02 2015-11-24 University Of Massachusetts Methods and compositions for controlling efficacy of rna silencing
EP1633770B1 (de) * 2003-06-13 2015-04-29 Alnylam Europe AG Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
EP1486564A1 (de) * 2003-06-13 2004-12-15 Ribopharma AG SiRNA mit erhöhter Stabilität in Serum
EP1636342A4 (de) * 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc Oligomere verbindungen zur verwendung bei der modulation von genen
ITRM20030335A1 (it) * 2003-07-09 2005-01-10 Univ Roma Sistema di espressione di sirna.
EP1670518B1 (de) 2003-09-12 2014-05-21 University of Massachusetts Rna-interferenz zur behandlung von funktionszunahmestörungen
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005078848A2 (en) 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1735009A4 (de) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Irna mittel targeting vegf
WO2005105157A2 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2471921A1 (de) * 2004-05-28 2012-07-04 Asuragen, Inc. Verfahren und Zusammensetzungen mit microRNA
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
EP1782321A4 (de) 2004-07-23 2009-11-04 Univ North Carolina Verfahren und materialien zur bestimmung von schmerzempfindlichkeit und vorhersage und behandlung zugehöriger störungen
US20060040391A1 (en) * 2004-08-20 2006-02-23 Promega Corporation RNA interference vectors
JP5087924B2 (ja) 2004-08-26 2012-12-05 日本新薬株式会社 ガラクトース誘導体、薬物担体及び医薬組成物
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
EP2302054B1 (de) * 2004-11-12 2014-07-16 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
US20070105803A1 (en) 2005-08-18 2007-05-10 Muthiah Manoharan Methods and compositions for treating neurological disease
CA2620387C (en) 2005-09-20 2018-09-18 Basf Plant Science Gmbh Methods for controlling gene expression using ta-sirna
US8093369B2 (en) 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
JP5111385B2 (ja) 2005-10-28 2013-01-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン遺伝子の発現を抑制するための組成物および方法
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
AU2006311730B2 (en) 2005-11-09 2010-12-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
CN101395168B (zh) 2006-03-01 2011-11-16 日本新药株式会社 半乳糖衍生物、药物载体及医药组合物
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
EP2527354A1 (de) 2006-03-31 2012-11-28 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5-Gens
EP3872179A1 (de) 2006-05-11 2021-09-01 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
WO2007137220A2 (en) 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
KR20090083338A (ko) 2006-09-18 2009-08-03 알닐람 파마슈티칼스 인코포레이티드 ＳＣＡＰ의 ＲＮＡｉ 조절 및 이들의 치료적 용도
AU2007299804A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
EP2104737B1 (de) * 2006-12-08 2013-04-10 Asuragen, INC. Funktionen und ziele von let-7-mikro-rnas
EP2104735A2 (de) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21-regulierte gene und pfade als ziele für therapeutische interventionen
JP2010516786A (ja) 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド ワクチンとしての使用のためのエキソソーム成分の改変
HUE027018T2 (en) 2007-03-21 2016-08-29 Brookhaven Science Ass Llc Combination hairpin antisense compositions and methods for modulating expression
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
AU2008232891B2 (en) 2007-03-29 2012-01-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the Ebola
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2167138A2 (de) * 2007-06-08 2010-03-31 Asuragen, INC. Mir-34-regulierte gene und pfade als targets für therapeutische intervention
CN103215269B (zh) 2007-07-05 2015-01-21 诺瓦提斯公司 用于治疗病毒感染的dsRNA
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
JP2010538678A (ja) * 2007-09-18 2010-12-16 イントラドイグム コーポレーション Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
JP5530933B2 (ja) 2007-12-10 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EA019531B1 (ru) 2008-03-05 2014-04-30 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ Eg5 И VEGF
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
WO2009114726A1 (en) * 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US20110166198A1 (en) * 2008-04-10 2011-07-07 Alnylam Pharmaceuticals, Inc. Rna compositions for modulating immune response
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
EP2326351B1 (de) * 2008-08-19 2017-12-27 Nektar Therapeutics Konjugate von kurzen interferierenden nukleinsäuren
EP2331690B1 (de) 2008-09-02 2016-01-13 Alnylam Pharmaceuticals Inc. Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
EP2334793B1 (de) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
IL302142B1 (en) 2008-10-20 2024-03-01 Alnylam Pharmaceuticals Inc Compounds and methods for inhibiting transthyretin expression
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
WO2010065834A1 (en) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
US20100267806A1 (en) 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
FR2944437B1 (fr) * 2009-04-16 2013-05-10 Oreal Utilisation d'inhibiteurs de l'expression d'hif 1 alpha pour proteger la peau des dommages deleteres induits par le rayonnement uva
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EA201270019A1 (ru) 2009-06-15 2012-06-29 Элнилэм Фармасьютикалз, Инк. Двуцепочечная рнк, включенная в липидный состав и мишенью которой является ген pcsk9
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
EP2464336A4 (de) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
JP5574258B2 (ja) 2009-10-01 2014-08-20 学校法人東京女子医科大学 膵臓がん治療用の組成物
CN102686729B (zh) 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
AU2011235276B2 (en) 2010-03-29 2015-09-03 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
EP2576579B1 (de) 2010-06-02 2018-08-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von leberfibrose
EP3372684B1 (de) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
CA3191066A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
WO2012177921A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
EP2723390B1 (de) 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
EP2700949A1 (de) 2012-08-24 2014-02-26 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Verwendung von Biliverdinreduktaseproteinen als Krebsmarker
DK2968424T3 (da) 2013-03-13 2020-03-30 Geneweave Biosciences Inc Ikke-replikative transduktionspartikler og transduktionspartikelbaserede reportersystemer
RU2015149680A (ru) 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
HUE048558T2 (hu) 2014-03-11 2020-07-28 Cellectis Eljárás allogén transzplantációra kompatibilis T-sejtek létrehozására
CA2974716A1 (en) 2014-11-12 2016-05-19 Nmc, Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
WO2016135732A1 (en) 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth
WO2016140922A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
CN108366966A (zh) 2015-08-24 2018-08-03 光环生物干扰疗法公司 用于调节基因表达的多核苷酸纳米颗粒及其用途
JP6941598B2 (ja) 2015-08-25 2021-09-29 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロタンパク質転換酵素サブチリシン／ケキシン（ｐｃｓｋ９）遺伝子関連障害を治療するための方法および組成物
US11072777B2 (en) 2016-03-04 2021-07-27 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
US20190367930A1 (en) 2016-07-29 2019-12-05 Danmarks Tekniske Universitet Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
CN111065731B (zh) 2017-06-16 2024-03-12 Imba-莫利库尔生物技术研究所 血管类器官、产生和使用所述类器官的方法
KR102527941B1 (ko) 2017-12-06 2023-05-02 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
WO1998005770A2 (de) * 1996-08-07 1998-02-12 Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Anti-sinn-rna mit sekundärstruktur
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000044895A1 (de) * 1999-01-30 2000-08-03 Roland Kreutzer Verfahren und medikament zur hemmung der expression eines vorgegebenen gens
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5712257A (en) 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
EP0378576B1 (de) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduktionsveränderte fibroblasten und ihre anwendung
EP0391960B1 (de) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetische modifizierung von endothelialen zellen
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
ATE152169T1 (de) 1988-02-05 1997-05-15 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
AU659824B2 (en) 1990-10-31 1995-06-01 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
JP3530186B2 (ja) 1992-03-05 2004-05-24 アイシス・ファーマシューティカルス・インコーポレーテッド 共有架橋オリゴヌクレオチド
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5674683A (en) 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
EP1117776A1 (de) 1998-10-09 2001-07-25 Ingene, Inc. Enzymatische synthese von ssdna
CA2345936A1 (en) 1998-10-09 2000-04-20 Ingene, Inc. Production of ssdna in a cell
US6200924B1 (en) 1999-01-29 2001-03-13 E. I. Du Pont De Nemours And Company Porous highly fluorinated acidic polymer catalyst
EP1171586B1 (de) 1999-04-21 2013-06-12 Alnylam Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur hemmung der funktion der polynukleotide sequenzen
CN101348785A (zh) 1999-05-10 2009-01-21 辛根塔参与股份公司 病毒基因表达的调节
US6569623B1 (en) 1999-09-08 2003-05-27 Ramot University Authority For Applied Research & Industrial Development Ltd. Genetic screening methods
US6861220B2 (en) 1999-09-08 2005-03-01 Ramot University Authority For Applied Research & Industrial Development Ltd Genetic screening methods
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
RU2164944C1 (ru) 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Способ изменения генетических свойств организма
GB9930691D0 (en) 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
WO2001070949A1 (en) 2000-03-17 2001-09-27 Benitec Australia Ltd Genetic silencing
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
ATE513910T1 (de) 2000-05-30 2011-07-15 Johnson & Johnson Res Pty Ltd Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
US20040053869A1 (en) 2000-08-19 2004-03-18 Peter Andrews Stem cell differentiation
US20030190635A1 (en) 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
WO2002061034A2 (en) 2000-12-08 2002-08-08 Invitrogen Corporation Compositions and methods for rapidly generating recombinant nucleic acid molecules
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7521548B2 (en) 2001-02-07 2009-04-21 Burnham Institute For Medical Research Apoptosis modulator Bcl-B and methods for making and using same
GB0104948D0 (en) 2001-02-28 2001-04-18 Novartis Res Foundation Novel methods
US20020132346A1 (en) 2001-03-08 2002-09-19 Jose Cibelli Use of RNA interference for the creation of lineage specific ES and other undifferentiated cells and production of differentiated cells in vitro by co-culture
WO2003070972A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
IL159756A0 (en) 2001-07-12 2004-06-20 Univ Massachusetts IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
WO2003012052A2 (en) 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
WO2003016572A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Oligonucleotide therapeutics for treating hepatitis c virus infections
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
CN1604783A (zh) 2001-10-26 2005-04-06 里伯药品公司 通过rna干扰治疗纤维化疾病的药物
WO2003035870A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung eines pankreaskarzinoms
US20040248835A1 (en) 2001-10-26 2004-12-09 Anja Krebs Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
DE10230996A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Behandlung eines Pankreaskarzinoms
WO2004033620A2 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US20030148341A1 (en) 2001-11-15 2003-08-07 Sin Wun Chey Gene amplification and overexpression in cancer
EP1442143A4 (de) 2002-02-20 2005-02-16 Sirna Therapeutics Inc DURCH RNA-INTERFERENZ VERMITTELTE HEMMUNG DER BCL2-GENEXPRESSION UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)
ATE519774T1 (de) 2002-02-20 2011-08-15 Sirna Therapeutics Inc Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
WO2003070283A2 (en) 2002-02-22 2003-08-28 Klaus Strebhardt Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
US20030180756A1 (en) 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
EA017847B1 (ru) 2005-01-07 2013-03-29 Элнилэм Фармасьютикалз, Инк. Композиция для лечения респираторных синцитиальных вирусов

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
WO1998005770A2 (de) * 1996-08-07 1998-02-12 Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Anti-sinn-rna mit sekundärstruktur
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2000044895A1 (de) * 1999-01-30 2000-08-03 Roland Kreutzer Verfahren und medikament zur hemmung der expression eines vorgegebenen gens

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMBROS VICTOR: "Dicing up RNAs", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 293, no. 5531, 3 August 2001 (2001-08-03), pages 811 - 813, XP002183122, ISSN: 0036-8075 *
BASS BRENDA L: "Double-stranded RNA as a template for gene silencing", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 101, no. 3, 28 April 2000 (2000-04-28), pages 235 - 238, XP002194756, ISSN: 0092-8674 *
GAUTSCHI O., TSCHOPP S., OLIE R.A. ET AL: "Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.", J. NATL. CANCER INST., vol. 93, no. 6, 21 March 2001 (2001-03-21), pages 463 - 471, XP009003270 *
ZAMORE PHILLIP D ET AL: "RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 101, no. 1, 31 March 2000 (2000-03-31), pages 25 - 33, XP002208683, ISSN: 0092-8674 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790922B2 (en) 2000-03-30 2014-07-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US9193753B2 (en) 2000-03-30 2015-11-24 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US9012138B2 (en) 2000-03-30 2015-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US8394628B2 (en) 2000-03-30 2013-03-12 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8420391B2 (en) 2000-03-30 2013-04-16 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US9012621B2 (en) 2000-03-30 2015-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US8552171B2 (en) 2000-03-30 2013-10-08 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8632997B2 (en) 2000-03-30 2014-01-21 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8742092B2 (en) 2000-03-30 2014-06-03 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8796016B2 (en) 2000-12-01 2014-08-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8445237B2 (en) 2000-12-01 2013-05-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8765930B2 (en) 2000-12-01 2014-07-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8362231B2 (en) 2000-12-01 2013-01-29 Max-Planck-Gesellschaft zur Föderung der Wissenschaften E.V. RNA interference mediating small RNA molecules
US8853384B2 (en) 2000-12-01 2014-10-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8895721B2 (en) 2000-12-01 2014-11-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8895718B2 (en) 2000-12-01 2014-11-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8933044B2 (en) 2000-12-01 2015-01-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8993745B2 (en) 2000-12-01 2015-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8778902B2 (en) 2000-12-01 2014-07-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8372968B2 (en) 2000-12-01 2013-02-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Also Published As

Publication number Publication date
EP2213736A3 (de) 2010-09-01
ATE460481T1 (de) 2010-03-15
US7473525B2 (en) 2009-01-06
DE10100586C1 (de) 2002-04-11
EP1349927B1 (de) 2010-03-10
CN1650010A (zh) 2005-08-03
US20040001811A1 (en) 2004-01-01
CA2432341A1 (en) 2002-07-18
WO2002055692A2 (de) 2002-07-18
EP2213736A2 (de) 2010-08-04
EP2365075A1 (de) 2011-09-14
ZA200304500B (en) 2003-11-18
JP4209678B2 (ja) 2009-01-14
EP2213736B1 (de) 2018-03-07
EP1349927A2 (de) 2003-10-08
ES2204360T3 (es) 2010-07-06
DE50214266D1 (de) 2010-04-22
ZA200304127B (en) 2004-05-11
ES2204360T1 (es) 2004-05-01
JP2004519457A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
WO2002055692A3 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
CA2513809A1 (en) Lipophilic derivatives of double-stranded ribonucleic acid
WO2007134161A8 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2007051045A3 (en) Compositions and methods for inhibiting expression of huntingtin gene
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
WO2002055693A3 (de) Verfahren zur hemmung der expression eines zielgens
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
CO6241169A2 (es) Metodos para el tratamiento de hipercolesterolemia
WO2007115168A8 (en) Compositions and methods for inhibiting expression of eg5 gene
WO2001048183A3 (en) Improvements relating to double-stranded rna inhibition
WO2005014782A8 (en) Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2008036933A3 (en) Compositions and methods for inhibiting expression of the hamp gene
WO2004046160A8 (en) Amino-lna, thio-lna and alpha-l-oxy-ln
WO2008109472A3 (en) Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof
WO2006032041A3 (en) Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2006119266A3 (en) Human micrornas and methods for inhibiting same
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
WO2004001013A3 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10384260

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002702247

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 540/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200304500

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002235826

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2432341

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002556739

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028035550

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002702247

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642